Tag: NTLA

CRISPR Shows Promise for Hereditary Angioedema in First-in-Human Trial

LOUISVILLE, Ky. — The future medical promise of CRISPR/Cas9 gene-editing appears to be a present-day reality for a small group of patients with the rare genetic condition known as hereditary angioedema (HAE). Interim results reported here from a phase I/II study involving 10 HAE patients showed a single infusion of…

Continue Reading CRISPR Shows Promise for Hereditary Angioedema in First-in-Human Trial

Intellia Therapeutics Presents New Interim Data from

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts have an ongoing attack-free interval through latest follow-up First three patients treated have an ongoing attack-free interval of 5.5 – 10.6 months after a…

Continue Reading Intellia Therapeutics Presents New Interim Data from

Intellia Therapeutics : In vivo CRISPR/Cas9 editing of KLKB1 in patients with HAE

In vivo CRISPR/Cas9 editing of KLKB1 in patients with HAE Hilary Longhurst1, Lauré M. Fijen2, Karen Lindsay1, Carri Boiselle3, James Butler3, Adele Golden3, David Maag3, Joseph Vogel3, Yuanxin Xu3, and Danny M. Cohn2 1Auckland District Health Board and University of Auckland, New…

Continue Reading Intellia Therapeutics : In vivo CRISPR/Cas9 editing of KLKB1 in patients with HAE

Editas Medicine: Clinical Hold Lifted; Management Upbeat (NASDAQ:EDIT)

gorodenkoff/iStock via Getty Images The discovery of the CRISPR gene-editing tool has helped medical companies develop immunological defenses and curative systems against pathogens. Notable companies using this technology include CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), and Editas Medicine (NASDAQ:EDIT). Editas has an expansive pipeline under research. It includes Vivo gene-edited…

Continue Reading Editas Medicine: Clinical Hold Lifted; Management Upbeat (NASDAQ:EDIT)

Intellia: Slim Hopes Of Near-Term Commercial Revenue, Bearish

liulolo/iStock via Getty Images Investment Thesis If you had invested in the CRISPR / Cas9 gene editing pioneer Intellia Therapeutics (NASDAQ:NTLA) five years ago, you would likely be well satisfied with your return to date – a ~285% return on your investment – although you may also feel that it…

Continue Reading Intellia: Slim Hopes Of Near-Term Commercial Revenue, Bearish

Intellia and Regeneron Present – GuruFocus.com

Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic modeling and simulation indicated that an 80 mg fixed dose provides similar exposure to the 1.0 mg/kg dose,…

Continue Reading Intellia and Regeneron Present – GuruFocus.com

Intellia (NTLA) Drops 4.76% on May 5

Last Price $ Last Trade Change $ Change Percent % Open $ Prev Close $ High $ low $ 52 Week High $ 52 Week Low $ Market Cap PE Ratio Volume Exchange NTLA – Market Data & News Trade Intellia Therapeutics Inc (NASDAQ: NTLA) shares are down 4.76%, or $2.65 per…

Continue Reading Intellia (NTLA) Drops 4.76% on May 5

Intellia gets upgrade at Brookline amid ‘unchanged’ patent risk on CRISPR/Cas9 technology

Andy/iStock via Getty Images Intellia Therapeutics (NTLA -3.1%) was upgraded by Brookline Capital Management to Buy from Hold with a $91 price target. Brookline analyst Leah Cann said the patent risk is unchanged, but the valuation has become attractive. In February, the U.S. Patent and Trademark Office backed the Broad…

Continue Reading Intellia gets upgrade at Brookline amid ‘unchanged’ patent risk on CRISPR/Cas9 technology

Validea Motley Fool Strategy Daily Upgrade Report – 2/26/2022

The following are today’s upgrades for Validea’s Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance. EXLSERVICE HOLDINGS, INC. (EXLS) is a mid-cap growth stock in the Business Services industry. The rating…

Continue Reading Validea Motley Fool Strategy Daily Upgrade Report – 2/26/2022

Intellia (NTLA) falls 3.55% for February 11

Last Price $ Last Trade Change $ Change Percent % Open $ Prev Close $ High $ low $ 52 Week High $ 52 Week Low $ Market Cap PE Ratio Volume Exchange NTLA – Market Data & News Trade Intellia Therapeutics Inc (NASDAQ: NTLA), a Cambridge, Massachusetts, company,…

Continue Reading Intellia (NTLA) falls 3.55% for February 11

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

This story originally appeared on Zacks Editas Medicine, Inc. EDIT has made rapid progress in the development of its lead pipeline candidate, EDIT-101, which employs CRISPR gene editing, to treat Leber congenital amaurosis type 10 (LCA10) — a rare genetic illness that causes blindness. – Zacks The company is evaluating…

Continue Reading Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

Intellia (NTLA) falls 5.68% on Moderate Volume September 20

Last Price $ Last Trade Change $ Change Percent % Open $ Prev Close $ High $ low $ 52 Week High $ 52 Week Low $ Market Cap PE Ratio Volume Exchange NTLA – Market Data & News Trade Intellia Therapeutics Inc (NASDAQ: NTLA), a Cambridge, Massachusetts, company,…

Continue Reading Intellia (NTLA) falls 5.68% on Moderate Volume September 20

FDA clears IND application for CRISPR-edited T-cell receptor therapy to treat AML

September 17, 2021 1 min read ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process…

Continue Reading FDA clears IND application for CRISPR-edited T-cell receptor therapy to treat AML

Intellia Therapeutics Set to Enter Clinic with First Solo Ex Vivo Candidate

Courtesy Intellia Therapeutics Intellia Therapeutics is celebrating another first today as the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for NTLA-5001, its first wholly-owned ex vivo CRISPR genome editing candidate. NTLA-5001 is being developed for the treatment of acute myeloid leukemia (AML). Intellia…

Continue Reading Intellia Therapeutics Set to Enter Clinic with First Solo Ex Vivo Candidate

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia | DNA RNA and Cells

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia Details Category: DNA RNA and Cells Published on Thursday, 16 September 2021 17:52 Hits: 130 NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering…

Continue Reading Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia | DNA RNA and Cells

Intellia (NTLA) falls 7.65% to Close at $163.25 on September 7

Last Price $ Last Trade Change $ Change Percent % Open $ Prev Close $ High $ low $ 52 Week High $ 52 Week Low $ Market Cap PE Ratio Volume Exchange NTLA – Market Data & News Trade Intellia Therapeutics Inc (NASDAQ: NTLA), a Cambridge, Massachusetts, company,…

Continue Reading Intellia (NTLA) falls 7.65% to Close at $163.25 on September 7

CRISPR-Based Therapeutics Blaze an In Vivo Path to the Clinic

Therapeutic applications of genome editing were envisioned at least as early as the mid-1990s, when the first sequence-specific genome editing technologies emerged. Initially, such applications were considered distant prospects, but by 2012, they suddenly seemed near to hand. It was at that time that CRISPR technologies emerged. CRISPR, which stands…

Continue Reading CRISPR-Based Therapeutics Blaze an In Vivo Path to the Clinic

Biotech Company Driven by Cutting Edge Science and Patients, Not Ego

Photo courtesy of Intellia Therapeutics Sports fans know that nothing is better for the chemistry of a team than winning, and on the CRISPR field, Intellia Therapeutics is on a winning streak.    On June 26, Intellia set the biotech world on fire, announcing the first-ever clinical data supporting the safety…

Continue Reading Biotech Company Driven by Cutting Edge Science and Patients, Not Ego

Intellia (NTLA) falls 5.48% on Moderate Volume August 19

Last Price $ Last Trade Change $ Change Percent % Open $ Prev Close $ High $ low $ 52 Week High $ 52 Week Low $ Market Cap PE Ratio Volume Exchange NTLA – Market Data & News Trade Intellia Therapeutics Inc (NASDAQ: NTLA) shares fell 5.48%, or $8.36…

Continue Reading Intellia (NTLA) falls 5.48% on Moderate Volume August 19

Therapeutic Advances Using In Vivo CRISPR Genome Editing

Broadcast Date: September 16, 2021Time: 8 am PT, 11 am ET, 17:00 CET When CRISPR-Cas9 gene-editing technology exploded onto the life science stage almost a decade ago, it was widely touted as a potentially curative therapy for many genetic diseases, using various ex vivo and in vivo delivery methods. That promise is…

Continue Reading Therapeutic Advances Using In Vivo CRISPR Genome Editing

Another Milestone for CRISPR-Cas9 Technology: First Trial Data for Treatment Delivered Intravenously

Unlike most other CRISPR/Cas-9 therapies that are ex vivo treatments in which cells are modified outside the body, this study was successful with an in vivo treatment Use of CRISPR-Cas9 gene editing technology for therapeutic purposes can be a boon for clinical laboratories. Not only is this application a step…

Continue Reading Another Milestone for CRISPR-Cas9 Technology: First Trial Data for Treatment Delivered Intravenously

Editas (EDIT) Up More Than 70% in Past 3 Months: Here’s Why

Shares of Editas Medicine, Inc. EDIT have rallied 78.7% in the past three months compared with the industry’s increase of 7.4%. Zacks Investment Research Image Source: Zacks Investment Research The company has made rapid progress in the development of its lead pipeline candidate, EDIT-101, in this time frame. EDIT-101 employs…

Continue Reading Editas (EDIT) Up More Than 70% in Past 3 Months: Here’s Why

Let’s Get Some Trading Intelligence on Intellia Therapeutics

By BRUCE KAMICH Aug 12, 2021 | 12:31 PM EDT Stocks quotes in this article: NTLA, IWM, AMC Intellia Therapeutics Inc. (NTLA)  is one of the largest holdings in the iShares Russell 2000 exchange-traded fund  (IWM)  and one Real Money subscriber wonders if this stock can help the IWM break out…

Continue Reading Let’s Get Some Trading Intelligence on Intellia Therapeutics